New automated multiplex assay for bone turnover markers in osteoporosis

被引:63
作者
Claudon, Aurelie [1 ]
Vergnaud, Philippe [1 ]
Valverde, Cecile [1 ]
Mayr, Anita [2 ]
Klause, Ursula [2 ]
Garnero, Patrick [1 ,3 ]
机构
[1] CCBR SYNARC, Biochem Markers, F-69003 Lyon, France
[2] Roche Diagnost, Penzberg, Germany
[3] INSERM, Res Unit 664, F-69008 Lyon, France
关键词
D O I
10.1373/clinchem.2008.105866
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
BACKGROUND: Serum C-terminal cross-linked telopeptide of type I collagen (CTX-I), N-terminal propeptide of type I Collagen (PIMP), and osteocalcin (OC) are among the most sensitive bone turnover markers for evaluating osteoporosis. Each marker is currently measured individually by manual or automated immuno-assays that are time consuming and require substantial sample volume. We evaluated the performance characteristics of a novel, fully automated, protein-array chip system that allows the simultaneous measurement of CTX-I, PINP, OC, and intact parathyroid hormone (PTH) in 20 mu L of serum. METHODS: We measured CTX-I, PINP, OC, and PTH using multiplex and corresponding automated single assays in 157 healthy premenopausal women, 74 healthy men, and 56 postmenopausal osteoporotic women before and 6 months after treatment with oral ibandronate (150 mg/month). RESULTS: Within- and between-run CVs of the multiplex assay were similar to those of single measurement assays (<10% for all markers), whereas the limit of quantification was lower, except for OC. Multiplex values highly correlated (r > 0.93, P < 0.0001 for all markers) with the corresponding single assays, and measured concentrations were comparable. After 6 months of ibandronate, CTX-I, PINP, and OC decreased by a median of 48%, 63%, and 52%, respectively (P < 0.0001 for all 3 markers), magnitudes similar to those of the corresponding single assays. CONCLUSIONS: The automated protein-array chip demonstrated similar analytical precision, improved analytical sensitivity, and comparable measured concentrations to those of single assays. The multiplex assay should be useful for assessing bone metabolism in large clinical studies, particularly when sample volume is limited. (C) 2008 American Association for Clinical Chemistry.
引用
收藏
页码:1554 / 1563
页数:10
相关论文
共 20 条
[1]   Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial [J].
Bauer, DC ;
Black, DM ;
Garnero, P ;
Hochberg, M ;
Ott, S ;
Orloff, J ;
Thompson, DE ;
Ewing, SK ;
Delmas, PD .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) :1250-1258
[2]   STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].
BLAND, JM ;
ALTMAN, DG .
LANCET, 1986, 1 (8476) :307-310
[3]   Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease - Potential uses and pitfalls [J].
Cremers, Serge ;
Garnero, Patrick .
DRUGS, 2006, 66 (16) :2031-2058
[4]   Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: Review of statistical analysis - Response [J].
Eastell, Richard ;
Hannon, Rosemary A. ;
Garnero, Patrick ;
Campbell, Michael J. ;
Delmas, Pierre D. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 (11) :1656-1660
[5]   Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone [J].
Garnero, P ;
Fledelius, C ;
Gineyts, E ;
Serre, CM ;
Vignot, E ;
Delmas, PD .
JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 (09) :1407-1415
[6]  
Garnero P., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P50
[7]  
Garnero P, 2001, CLIN CHEM, V47, P694
[8]  
GARNERO P, 1998, DYNAMICS BONE CARTIL, P465
[9]   Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis [J].
Garnero, Patrick ;
Vergnaud, Philippe ;
Hoyle, Nicholas .
CLINICAL CHEMISTRY, 2008, 54 (01) :188-196
[10]   Vitamin D deficiency [J].
Holick, Michael F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (03) :266-281